Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. In addition, the Company develops Cemdisiran to treat complement-mediated diseases, Belcesiran for the treatment of alpha-1 liver disease, Elebsiran, Zilebesiran, ALN-APP, ALN-HSD, Fitusiran, and others.

Employees

2,230

Sector

Pharmaceuticals

Calendar

Jul. 30 - Q2 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
25-07-10	322.64 $	+0.55%	489,398
25-07-09	320.87 $	+1.06%	1,039,484
25-07-08	317.50 $	-2.05%	972,969
25-07-07	324.13 $	-2.34%	1,294,593
25-07-03	331.91 $	+0.65%	431,157

Delayed Quote Nasdaq, July 10, 2025 at 04:00 pm EDT

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

322.64USD

Average target price

327.51USD

Spread / Average Target

+1.51%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 04:00:00 2025-07-10 pm EDT			5-day change	1st Jan Change
322.64 ^USD	+0.55%		-2.79%	+37.11%

Jul. 09	Alnylam Pharmaceuticals, Inc., Q1 2025 Earnings Call, May 01, 2025
Jul. 07	Alnylam Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 09:20 AM

Capitalization	42.07B 35.99B 33.54B 31.02B 57.57B 3,607B 64.1B 401B 153B 1,686B 158B 155B 6,160B	P/E ratio 2025 *	-369x	P/E ratio 2026 *	169x
Enterprise value	40.35B 34.52B 32.17B 29.75B 55.22B 3,460B 61.48B 385B 147B 1,617B 151B 148B 5,909B	EV / Sales 2025 *	13.7x	EV / Sales 2026 *	10.3x
Free-Float	99.2%	Yield 2025 *	-	Yield 2026 *	-

Alnylam Pharmaceuticals, Inc., Q1 2025 Earnings Call, May 01, 2025	Jul. 09
Alnylam Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 09:20 AM	Jul. 07
RBC Raises Price Target on Alnylam Pharmaceuticals to $350 From $330, Keeps Outperform Rating	Jul. 07	MT
Alnylam Pharmaceuticals, Inc.(NasdaqGS:ALNY) dropped from Russell 3000E Value Index	Jun. 30	CI
Alnylam Pharmaceuticals, Inc.(NasdaqGS:ALNY) dropped from Russell Midcap Value Index	Jun. 30	CI
Alnylam Pharmaceuticals, Inc.(NasdaqGS:ALNY) dropped from Russell 3000 Value Index	Jun. 30	CI
Alnylam Pharmaceuticals, Inc.(NasdaqGS:ALNY) dropped from Russell Small Cap Comp Value Index	Jun. 30	CI
Alnylam Pharmaceuticals, Inc.(NasdaqGS:ALNY) dropped from Russell 1000 Value Index	Jun. 30	CI
Alnylam Pharmaceuticals, Inc.(NasdaqGS:ALNY) dropped from Russell Small Cap Comp Value Benchmark	Jun. 29	CI
Alnylam Pharmaceuticals, Inc.(NasdaqGS:ALNY) dropped from Russell 3000E Value Benchmark	Jun. 29	CI
Alnylam Pharmaceuticals, Inc.(NasdaqGS:ALNY) dropped from Russell 3000 Value Benchmark	Jun. 29	CI
Alnylam Pharmaceuticals, Inc.(NasdaqGS:ALNY) dropped from Russell Midcap Value Benchmark	Jun. 29	CI
Alnylam Pharmaceuticals, Inc.(NasdaqGS:ALNY) dropped from Russell 1000 Value Benchmark	Jun. 29	CI

RBC Raises Price Target on Alnylam Pharmaceuticals to $350 From $330, Keeps Outperform Rating	Jul. 07	MT
UBS Adjusts Alnylam Pharmaceuticals Price Target to $349 From $331, Maintains Buy Rating	May. 02	MT
BofA Adjusts Price Target on Alnylam Pharmaceuticals to $328 From $325, Keeps Buy Rating	Apr. 17	MT
JPMorgan Upgrades Alnylam Pharmaceuticals to Overweight From Neutral, Adjusts Price Target to $328 From $280	Mar. 24	MT
Analyst recommendations: General Mills, Ulta Beauty, Micron Technology, RH…	Mar. 24

Alnylam Pharmaceuticals, Inc. Stock

Equities

ALNY

US02043Q1076

Pharmaceuticals

Valuation: Alnylam Pharmaceuticals, Inc.

Chart: Alnylam Pharmaceuticals, Inc.

Latest news: Alnylam Pharmaceuticals, Inc.

Last Transcript: Alnylam Pharmaceuticals, Inc.

Analysts' recommendations: Alnylam Pharmaceuticals, Inc.

Press Releases: Alnylam Pharmaceuticals, Inc.

News in other languages: Alnylam Pharmaceuticals, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Alnylam Pharmaceuticals, Inc.

ETFs: Alnylam Pharmaceuticals, Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

OXLUMO® (lumasiran injection) Now Reimbursed in Canada For the Treatment of Primary Hyperoxaluria Type 1 (PH1) in Pediatric and Adult Patients	Jul. 02	AQ
Federal Circuit Patent Watch: An Enabling Anticipatory Prior Art Reference Need Only Enable A Single Embodiment Of The Claim	Jun. 19	AQ
Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer	Jun. 18	BU
Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy	Jun. 09	BU
Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference	May. 28	BU

Alnylam reçoit une approbation de la Commission européenne pour l'AMVUTTRA® (vutrisiran) dans le traitement de la cardiomyopathie amyloïde ATTR	Jun. 10
Alnylam erhält von der Europäischen Kommission die Zulassung für AMVUTTRA® (Vutrisiran) zur Behandlung von ATTR-Amyloidose mit Kardiomyopathie	Jun. 10
Alnylam reçoit un avis favorable du CHMP pour le vutrisiran dans le traitement de la cardiomyopathie amyloïde ATTR	Apr. 29
Alnylam erhält positive CHMP-Stellungnahme für Vutrisiran zur Behandlung von ATTR-Amyloidose mit Kardiomyopathie	Apr. 29
USA-Les valeurs à suivre à Wall Street (actualisé)	Mar. 21

1 day	+0.55%
1 week	-2.79%
Current month	-1.06%
1 month	+6.67%
3 months	+42.58%
6 months	+35.57%
Current year	+37.11%

1 week	313.74	328.99
1 month	295.82	333.7
Current year	205.87	333.7
1 year	205.87	333.7
3 years	135.46	333.7
5 years	117.58	333.7
10 years	31.38	333.7

Manager	Title	Age	Since
Yvonne Greenstreet CEO	Chief Executive Officer	62	2021-12-31
Jeffrey Poulton DFI	Director of Finance/CFO	57	2019-08-12
Timothy J. Maines CTO	Chief Tech/Sci/R&D Officer	-	2023-03-31

Director	Title	Age	Since
Dennis Ausiello BRD	Director/Board Member	79	2012-04-22
Amy Schulman CHM	Chairman	64	2023-01-04
Michael Bonney CHM	Chairman	66	2015-11-30

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
ALNYLAM PHARMACEUTICALS, INC.	+0.55%	-2.79%	+25.17%	+111.58%	42.07B
ELI LILLY AND COMPANY	+0.47%	+1.46%	-15.21%	+139.25%	710B
JOHNSON & JOHNSON	+0.90%	+1.37%	+7.24%	-11.55%	379B
ABBVIE INC.	+2.30%	+2.23%	+16.04%	+27.58%	344B
NOVO NORDISK A/S	-0.95%	+3.21%	-53.70%	+11.45%	317B
ROCHE HOLDING AG	-1.18%	+0.97%	+4.46%	-20.32%	265B
NOVARTIS AG	-1.17%	+1.42%	-0.13%	+18.28%	244B
ASTRAZENECA PLC	-0.61%	+3.61%	-12.47%	-5.22%	223B
MERCK & CO., INC.	+0.37%	+1.98%	-33.34%	-9.44%	211B
AMGEN INC.	+1.30%	+0.71%	-6.62%	+20.88%	162B
Average	-0.04%	+1.10%	-6.86%	+28.25%	289.67B
Weighted average by Cap.	-0.02%	+1.07%	-9.74%	+38.52%

	2025 *	2026 *
Net sales	2.95B 2.52B 2.35B 2.17B 4.03B 253B 4.49B 28.09B 10.73B 118B 11.05B 10.82B 431B	3.87B 3.32B 3.09B 2.86B 5.3B 332B 5.9B 36.94B 14.11B 155B 14.53B 14.23B 567B
Net income	-119M -102M -94.69M -87.57M -163M -10.18B -181M -1.13B -432M -4.76B -445M -436M -17.39B	241M 206M 192M 178M 330M 20.68B 367M 2.3B 878M 9.66B 904M 886M 35.32B
Net Debt	-1.72B -1.47B -1.37B -1.27B -2.35B -147B -2.62B -16.39B -6.26B -68.89B -6.45B -6.32B -252B	-2.2B -1.88B -1.76B -1.62B -3.01B -189B -3.36B -21B -8.02B -88.27B -8.26B -8.09B -323B